Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention
Lindsey R. Baden(Brigham and Women's Hospital), Patricia Fast(International AIDS Vaccine Initiative), Maria Grazia-Pau(International AIDS Vaccine Initiative), Glenda Gray(South African Medical Research Council), Lauren Peter(Beth Israel Deaconess Medical Center), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Etienne Karita(Rwanda Biomedical Center), Len Dally(International AIDS Vaccine Initiative), Craig Innes(Aurum Institute), Liesl Page‐Shipp(International AIDS Vaccine Initiative), Linda‐Gail Bekker(Desmond Tutu HIV Foundation), Edith Swann(National Institutes of Health), Nicole Frahm(Fred Hutch Cancer Center), Dagna Laufer(International AIDS Vaccine Initiative), Dan H. Barouch(Beth Israel Deaconess Medical Center), Fatima Laher(University of the Witwatersrand), Peter Hayes(International AIDS Vaccine Initiative), Yehuda Z. Cohen(Rockefeller University), Mo Weijtens(Janssen (Netherlands)), Angela Lombardo(International AIDS Vaccine Initiative), Michael S. Seaman(Beth Israel Deaconess Medical Center), Jill Gilmour(International AIDS Vaccine Initiative), Josephine H. Cox(International AIDS Vaccine Initiative), Jerry Sadoff(International AIDS Vaccine Initiative), M. Juliana McElrath(Fred Hutch Cancer Center), Surita Roux(Desmond Tutu HIV Foundation), Omu Anzala(International AIDS Vaccine Initiative), Gaudensia Mutua, Raphael Dolin(Beth Israel Deaconess Medical Center), Nicole Grunenberg(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Julien Nyombayire(Rwanda Zambia HIV Research Group)
Cited by 84
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k